Bio-Rad Laboratories Crecimiento futuro

Future controles de criterios 3/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Bio-Rad Laboratories de 81.3% y 3.3% por año respectivamente. Se prevé que el BPA crezca en un 78.2% al año. Se espera que la rentabilidad financiera sea de 4.2% en 3 años.

Información clave

81.3%

Tasa de crecimiento de los beneficios

78.2%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Life Sciences	17.4%
Tasa de crecimiento de los ingresos	3.3%
Rentabilidad financiera futura	4.2%
Cobertura de analistas	Good
Última actualización	29 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Bio-Rad Laboratories (NYSE:BIO) Has A Pretty Healthy Balance Sheet

Apr 18

Bio-Rad: A Lackluster Picks-And-Shovels Life Science Company With A Key Investment Kicker

Apr 14

Bio-Rad: Business Returns Aren't Economically Valuable, Sartorius Now A Hindrance

Oct 25

At US$358, Is It Time To Put Bio-Rad Laboratories, Inc. (NYSE:BIO) On Your Watch List?

Oct 02

We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt

Aug 21

Bio-Rad: A Cash Flow Returns On Investments Analysis

Aug 10

Are Bio-Rad Laboratories, Inc. (NYSE:BIO) Investors Paying Above The Intrinsic Value?

Jul 30

Is It Too Late To Consider Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)?

Jul 04

Does Bio-Rad Laboratories (NYSE:BIO) Have A Healthy Balance Sheet?

May 23

A Look At The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

May 01

Why Bio-Rad Laboratories, Inc. (NYSE:BIO) Could Be Worth Watching

Apr 04

Bio-Rad Labs reports Q4 2022 results

Feb 16

Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?

Feb 10

Calculating The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Jan 20

Bio-Rad: How Efficient Is Its Capital Management? A Deep Look, With Technicals

Jan 04

Why Bio-Rad Laboratories, Inc. (NYSE:BIO) Could Be Worth Watching

Dec 08

Bio-Rad Labs Non-GAAP EPS of $2.60 misses by $0.17, revenue of $680.8M misses by $1.9M

Oct 27

A Look At The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Oct 14

Will Bio-Rad And Qiagen Merge? I Can't See Any Logic To This Deal

Oct 12

Bio-Rad Laboratories hits 52-week low; down 40% YTD

Sep 19

Is Bio-Rad Laboratories (NYSE:BIO) Using Too Much Debt?

Sep 02

Bio-Rad Labs Non-GAAP EPS of $3.38 beats by $0.67, revenue of $691.1M beats by $26.5M

Jul 28

When Should You Buy Bio-Rad Laboratories, Inc. (NYSE:BIO)?

Jul 25

Estimating The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Jul 04

Bio-Rad Laboratories (NYSE:BIO) Has A Rock Solid Balance Sheet

May 02

Bio-Rad Offers Value If You Look

Mar 28

Bio-Rad Laboratories: Relentless Growth Supports A Bullish Outlook

Dec 25

Is Now The Time To Look At Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)?

Dec 10

Previsiones de crecimiento de beneficios e ingresos

NYSE:BIO - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	2,932	790	708	875	3
12/31/2025	2,856	509	481	625	6
12/31/2024	2,713	444	235	404	6
12/31/2023	2,671	-637	218	375	N/A
9/30/2023	2,720	-159	223	374	N/A
6/30/2023	2,769	-428	153	287	N/A
3/31/2023	2,779	-191	125	242	N/A
12/31/2022	2,802	-3,628	80	194	N/A
9/30/2022	2,805	-6,021	152	286	N/A
6/30/2022	2,871	-1,930	364	505	N/A
3/31/2022	2,896	-91	459	606	N/A
12/31/2021	2,923	4,254	536	670	N/A
9/30/2021	2,980	6,659	670	783	N/A
6/30/2021	2,880	4,045	590	689	N/A
3/31/2021	2,701	4,098	533	626	N/A
12/31/2020	2,546	3,814	480	585	N/A
9/30/2020	2,380	3,521	378	450	N/A
6/30/2020	2,294	1,947	323	414	N/A
3/31/2020	2,329	1,579	383	478	N/A
12/31/2019	2,312	1,759	368	458	N/A
9/30/2019	2,304	377	272	403	N/A
6/30/2019	2,289	905	251	366	N/A
3/31/2019	2,292	574	169	288	N/A
12/31/2018	2,289	366	156	285	N/A
9/30/2018	2,294	1,277	148	250	N/A
6/30/2018	2,283	1,030	116	216	N/A
3/31/2018	2,212	767	98	201	N/A
12/31/2017	2,160	122	-11	104	N/A
9/30/2017	2,110	17	N/A	130	N/A
6/30/2017	2,085	13	N/A	153	N/A
3/31/2017	2,097	26	N/A	168	N/A
12/31/2016	2,068	26	N/A	216	N/A
9/30/2016	2,067	98	N/A	157	N/A
6/30/2016	2,028	97	N/A	188	N/A
3/31/2016	2,018	108	N/A	149	N/A
12/31/2015	2,019	109	N/A	186	N/A
9/30/2015	2,047	103	N/A	190	N/A
6/30/2015	2,108	97	N/A	199	N/A
3/31/2015	2,139	100	N/A	237	N/A
12/31/2014	2,175	89	N/A	273	N/A
9/30/2014	2,179	80	N/A	304	N/A
6/30/2014	2,154	61	N/A	268	N/A
3/31/2014	2,142	64	N/A	211	N/A
12/31/2013	2,133	78	N/A	169	N/A
9/30/2013	2,104	91	N/A	194	N/A
6/30/2013	2,098	141	N/A	211	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que BIO sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Se prevé que BIO sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que BIO sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (3.3% al año) de BIO crezcan más despacio que el mercado de US (8% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 3.3% al año) de BIO crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de BIO sea baja dentro de 3 años (4.2%).

Bio-Rad Laboratories Crecimiento futuro

Future controles de criterios 3/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Bio-Rad Laboratories, Inc. Updates Its Financial Outlook for Full-Year 2023

Price target decreased by 7.7% to US$560

Price target decreased to US$597

Price target decreased to US$647

Bio-Rad Laboratories, Inc. Provides Earnings Guidance for the Year 2022

Price target increased to US$705

Recent updates

Bio-Rad Laboratories, Inc. Announces Executive Vice President and President Changes, Life Science Group

Bio-Rad Laboratories, Inc. to Report Q1, 2024 Results on May 07, 2024

Bio-Rad Laboratories (NYSE:BIO) Has A Pretty Healthy Balance Sheet

Bio-Rad: A Lackluster Picks-And-Shovels Life Science Company With A Key Investment Kicker

Bio-Rad Laboratories, Inc. Announces Chief Operating Officer Andrew Last to Retire

Bio-Rad Laboratories, Inc., Annual General Meeting, Apr 23, 2024

Bio-Rad Laboratories, Inc. Appoints Roop K. Lakkaraju as New Executive Vice President Effective April 15, 2024

Insider notifies of intention to sell stock

Full year 2023 earnings: EPS misses analyst expectations

Bio-Rad Laboratories, Inc. Appoints Norman Schwartz as Principal Financial Officer

At US$325, Is Bio-Rad Laboratories, Inc. (NYSE:BIO) Worth Looking At Closely?

Bio-Rad Laboratories, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Are Investors Undervaluing Bio-Rad Laboratories, Inc. (NYSE:BIO) By 43%?

Bio-Rad Laboratories, Inc. Announces Resignation of Dara Grantham Wright as Executive Vice-President and President, Effective January 12, 2024

Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?

Third quarter 2023 earnings released: EPS: US$3.65 (vs US$5.52 loss in 3Q 2022)

Now 22% undervalued after recent price drop

Bio-Rad: Business Returns Aren't Economically Valuable, Sartorius Now A Hindrance

Bio-Rad Laboratories, Inc. Announces Resignation of Ilan Daskal, Chief Financial Officer, Effective November 6, 2023

Bio-Rad Laboratories, Inc. Announces Resignation of Ilan Daskal, Executive Vice-President and Principal Financial Officer, Effective November 6, 2023

Bio-Rad Laboratories, Inc. to Report Q3, 2023 Results on Oct 26, 2023

At US$358, Is It Time To Put Bio-Rad Laboratories, Inc. (NYSE:BIO) On Your Watch List?

New major risk - Revenue and earnings growth

Chairman exercised options and sold US$1.9m worth of stock

Bio-Rad Laboratories, Inc. Announces Executive Changes, Effective September 18, 2023

We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt

Bio-Rad: A Cash Flow Returns On Investments Analysis

Bio-Rad Laboratories, Inc. Updates Its Financial Outlook for Full-Year 2023

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Are Bio-Rad Laboratories, Inc. (NYSE:BIO) Investors Paying Above The Intrinsic Value?

Bio-Rad Laboratories, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Bio-Rad Laboratories, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Is It Too Late To Consider Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)?

Senior VP & Chief Accounting Officer recently sold US$73k worth of stock

Does Bio-Rad Laboratories (NYSE:BIO) Have A Healthy Balance Sheet?

Price target decreased by 7.7% to US$560

First quarter 2023 earnings released: EPS: US$2.33 (vs US$113 loss in 1Q 2022)

Executive VP & COO exercised options and sold US$156k worth of stock

A Look At The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Executive VP & CFO exercised options and sold US$113k worth of stock

Why Bio-Rad Laboratories, Inc. (NYSE:BIO) Could Be Worth Watching

Executive VP recently sold US$363k worth of stock

Executive VP notifies of intention to sell stock

Full year 2022 earnings released: US$122 loss per share (vs US$142 profit in FY 2021)

Bio-Rad Labs reports Q4 2022 results

Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?

Calculating The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Bio-Rad Laboratories, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Bio-Rad: How Efficient Is Its Capital Management? A Deep Look, With Technicals

Why Bio-Rad Laboratories, Inc. (NYSE:BIO) Could Be Worth Watching

Price target decreased to US$597

Senior VP & Chief Accounting Officer recently sold US$160k worth of stock

Price target decreased to US$647

Now 23% undervalued after recent price drop

Third quarter 2022 earnings: EPS misses analyst expectations

Bio-Rad Laboratories, Inc. Provides Earnings Guidance for the Year 2022

Bio-Rad Labs Non-GAAP EPS of $2.60 misses by $0.17, revenue of $680.8M misses by $1.9M

Bio-Rad Laboratories, Inc. to Report Q3, 2022 Results on Oct 27, 2022

A Look At The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Will Bio-Rad And Qiagen Merge? I Can't See Any Logic To This Deal

Now 24% undervalued after recent price drop

Bio-Rad Laboratories hits 52-week low; down 40% YTD

Price target increased to US$705

Chairman exercised options and sold US$373k worth of stock

Is Bio-Rad Laboratories (NYSE:BIO) Using Too Much Debt?

Senior VP & Chief Accounting Officer recently sold US$278k worth of stock

Bio-Rad Laboratories, Inc. (NYSE:BIO) agreed to acquire Curiosity Diagnostics Sp. z o.o. from Scope Fluidics S.A. (WSE:SCP) for $100 million.

Bio-Rad Laboratories, Inc. (NYSE:BIO) agreed to acquire Curiosity Diagnostics Sp. z o.o. from Scope Fluidics S.A. (WSE:SCP) for $100 million.